Harmony® Test is a non-invasive method for the detection of the fetal trisomies in the unborn child, based on the analysis of the genetic material (fetal DNA) that circulates in the mother’s blood.

The Harmony® Test is an early and reliable prenatal screening test for the mother’s blood after completion of the 10th week of gestation.

In chromosomally health fetuses, the genetic information is stored in 23 pairs of chromosomes. A trisomy is a chromosomal disorder in which a certain chromosome occurs three times instead of twice.

Trisomy 21 is the most common form of a chromosomal disorder at birth. It occurs in approximately one out of every 830 newborns. The probability of its occurrence depends to a large extent on the age of the mother. A trisomy 21 leads to “Down syndrome”, which can cause mild to moderate mental disability as well as other illnesses such as congenital heart diseases. The average life expectancy of affected persons today is around 60 years.

Trisomy 18 causes “Edwards syndrome”. This trisomy appears in approximately one out of every 5,000 newborns. Trisomy 13 (“Patau syndrome”) affects approximately one out of every 16,000 newborns. Both trisomies are associated with a high rate of miscarriage. Affected children suffer from several disorders simultaneously, including serious heart diseases. The mean life expectancy of babies affected by trisomy 18 or 13 is only a few months and they rarely survive their first year of life.

The Harmony® Test allows the detection of the most common chromosomal disorders in the unborn child by taking a sample of the mother’s blood.

Unlike invasive methods, the Harmony® Test carries no risk of miscarriage.

Especially for a fetal trisomy 21, the informative value of the Harmony® Test is far higher than other methods such as first trimester screening (ultrasound + hormone analysis)

The Harmony® Test allows the detection of the most common chromosomal disorders in the unborn child by taking a sample of the mother’s blood.

Unlike invasive methods, the Harmony® Test carries no risk of miscarriage.

Especially for a fetal trisomy 21, the informative value of the Harmony® Test is far higher than other methods such as first trimester screening (ultrasound + hormone analysis)

Fetal cell free DNA is released from the placenta into the maternal bloodstream. From gestational age 10+0 the amount of fetal DNA usually is sufficient for analysis.

DNA (genetic material) passes from the placenta to the mother’s blood and can be analysed for chromosomal disorders using the Harmony® Test. Although highly accurate, the Harmony® Test still must be regarded as a screening test in which false positive and false negative cases can occur.

The Harmony® Test is an non-invasive test to detect fetal trisomies 21, 18, 13, and sex chromosomal disorders. The test can be performed after the 10th week of pregnancy and has no risk of a procedure – related miscarriage.

No other NIPT method has been investigated as intensely in clinical studies as the Harmony® Test. If one summarises the most important studies published, the Harmony® Test has a detection rate of 99.3% for trisomy 21 (trisomy 18: 97.4%, trisomy 13: 93.8%)

In a large interdisciplinary analysis exact data on the false positive rate of the Harmony® Test could be determined in an unselected patient collective. The false positive rate for more than 23:155 pregnant women for trisomy 21 is 0.04% (trisomy 13 and trisomy 18: 0.02% each) and thus about 125 times lower than in the first trimester screening which had a false positive rate of about 5%.